Abstract
1–Methyl–4–phenyl–1,2/3,6–tetrahydropyridine (MPTP) produces clinical, biochemical and neuropathologic changes reminiscent of those which occur in idiopathic Parkinson's disease. 7–Nitroindazole (7–NI) is a relatively selective inhibitor of the neuronal isoform of nitric oxide synthase (NOS) that blocks MPTP neurotoxicity in mice. We now show that 7–NI protects against profound striatal dopamine depletions and loss of tyrosine hydroxylase–positive neurons in the substantia nigra in MPTP–treated baboons. Furthermore, 7–NI protected against MPTP–induced motor and frontal–type cognitive deficits. These results strongly implicate a role of nitric oxide in MPTP neurotoxicity and suggest that inhibitors of neuronal NOS might be useful in treating Parkinson's disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burns, R.S. et al. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc. Nath Acad. Sci. USA 80, 4546–4550 (1983).
Bloem, B.R. et al. The MPTP model: Versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neuroh Sci. 97, 273–293 (1990).
Langston, J.W., Ballard, P., Tetrud, J.W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983).
Hantraye, P. et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons. Neuroscience 53, 169–178 (1993).
Varastet, M., Riche, D., Maziere, M. & Hantraye, P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63, 47–56 (1994).
Forno, L.S., Langston, J.W., DeLanney, L.E., Irwin, I. & Ricaurte, G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neuroh 20, 449–455 (1986).
Tipton, K.F. & Singer, T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191–1206 (1993).
Beal, M.F., Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neuroh 38, 357–366 (1995).
Dawson, V.L. et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Nath Acad. Sci. USA 88, 6368–6371 (1991).
Dawson, V.L. et al. Mechanisms of nitric oxide mediated neurotoxicity in primary brain cultures. J. Neurosci. 13, 2651–2661 (1993).
Schulz, J.B., Matthews, R.T., Muqit, M.M.K., Browne, S.E. & Beal, M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MFTP-induced neurotoxicity in mice. J. Neurochem. 64, 936–939 (1995a)
Przedborski, S. et al Role of nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc. Nath Acad. Sci. USA 93, 4565–4571 (1996).
German, D.C., Dubach, M., Askari, S., Speciale, S.G. & Bowden, D.M. 1-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? Neuroscience 24, 161–174 (1988).
Schneider, J.S. Behavioral and neuropathological consequences of chronic exposure to low doses of the dopaminergic neurotoxin MPTP. in The Vulnerable Brain and Environmental Risks (eds. Isaacson, R.L. & Jensen, K.F.) 293–308 (Plenum, New York, 1992).
Lipton, S.A. et al. A redox-based mechanism for the neuroprotective and neu-rodestructive effects of nitric oxide and related nitroso-compounds. Nature 364, 626–632 (1993).
Schulz, J.B. et al. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15, 8419–8429 (1995b).
Beckman, J.S. et al. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochem. Biophys. 298, 438–445 (1992).
Ischiropoulos, H. et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431–437 (1992).
Wolff, D.J. & BJThe inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents. Arch. Biochem. Biophys. 311, 300–306 (1994).
Babbedge, R.C. et al. Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br. J. Pharmacol. 110, 225–228 (1993).
Przedborski, S. et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658–1667 (1992).
Diamond, A. Developmental time course in human infants and infant monkeys, and the neural bases of inhibitory control in reaching. Ann. N.Y. Acad. Sci. 608, 637–669 (1990).
Palfi, S. et al Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington disease. J. Neurosci. (in the press).
Lin, A.M.-Y., Kao, L.-S. & Chai, C.Y. Involvement of nitric oxide in dopaminergic transmission in rat striatum: An in vivo electrochemical study. J. Neurochem . 65, 2043–2049 (1995).
Lonart, G. & Johnson, K.M. Inhibitory effects of nitric oxide on the uptake of [3H]dopamine and [3H]glutamate by striatal synaptosomes. J. Neurochem. 63, 2108–2117 (1994).
Silva, M.T. et al. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Br. J. Pharmacol. 114, 257–258 (1995).
Brouillet, E. et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Nath Acad. Sci. USA 92, 7105–7109 (1995).
Beal, M.F., Kowall, N.W., Swartz, K.J. & Ferrante, R. Homocysteic acid striatal lesions in rats spare somatostatin-neuropeptide Y neurons. Neurosci. Lett. 108, 36–42 (1990).
Ferrante, R.J., Kowall, N.W., Cipolloni, P.B., Storey, E. & Beal, M.F. Excitotoxin lesions in primates as a model of Huntington's disease: Histopathologic and neurochemical characterization. Exp. Neuroh 119, 46–71 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hantraye, P., Brouillet, E., Ferrante, R. et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons. Nat Med 2, 1017–1021 (1996). https://doi.org/10.1038/nm0996-1017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0996-1017
This article is cited by
-
Arsenic alters nitric oxide signaling similar to autism spectrum disorder and Alzheimer’s disease-associated mutations
Translational Psychiatry (2022)
-
MicroRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson’s Disease
Neurochemical Research (2021)
-
The Peculiar Facets of Nitric Oxide as a Cellular Messenger: From Disease-Associated Signaling to the Regulation of Brain Bioenergetics and Neurovascular Coupling
Neurochemical Research (2021)
-
RNA-binding protein RBM3 prevents NO-induced apoptosis in human neuroblastoma cells by modulating p38 signaling and miR-143
Scientific Reports (2017)
-
The Brain NO Levels and NOS Activities Ascended in the Early and Middle Stages and Descended in the Terminal Stage in Scrapie-Infected Animal Models
Molecular Neurobiology (2017)